Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Global Clinical Trials Review 2024, Featuring Takeda Pharmaceutical, JCR Pharmaceuticals, GC Corp, RegenxBio, Sangamo Therapeutics and Generium
02 avr. 2024 09h48 HE
|
Research and Markets
Dublin, April 02, 2024 (GLOBE NEWSWIRE) -- The "Mucopolysaccharidosis II (Mps II) (Hunter Syndrome ) - Global Clinical Trials Review, 2024" clinical trials has been added to ...
Global AI-based Clinical Trial Solutions Market Projected to Reach $5.65 Billion by 2028
01 avr. 2024 18h04 HE
|
Research and Markets
Dublin, April 01, 2024 (GLOBE NEWSWIRE) -- The "AI-based Clinical Trial Solution Providers Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. Market Growth...
Clinical Trial Supplies Market Report 2024-2034 - Rising Demand for Biologics Propelling Growth of Cold Chain Distribution Supplies
29 mars 2024 05h20 HE
|
Research and Markets
Dublin, March 29, 2024 (GLOBE NEWSWIRE) -- The "Clinical Trial Supplies Market Report 2024-2034" report has been added to ResearchAndMarkets.com's offering.World revenue for the Clinical Trial...
Global Clinical Trial Supply & Logistics Market for Pharmaceutical Industry Poised for Growth, Reaching USD 6.9 Billion by 2028
27 mars 2024 13h13 HE
|
Research and Markets
Dublin, March 27, 2024 (GLOBE NEWSWIRE) -- The "Global Clinical Trial Supply & Logistics for Pharmaceutical Industry Market (2023-2028) Competitive Analysis, Impact of Economic Slowdown &...
Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund
26 mars 2024 10h25 HE
|
ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, March 27, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company...
PharmAla Biotech Signs Sale Agreement with Numinus
26 mars 2024 08h55 HE
|
PharmAla Biotech
PharmAla announces binding sales order from Numinus Wellness, as well as a recent presentation of data to the Behaviour, Biology, and Chemistry Conference
Healis Therapeutics announces collaboration with Massachusetts General Hospital (MGH) and affiliates of Harvard Medical School to advance clinical-stage neuroscience research
26 mars 2024 08h00 HE
|
Healis Therapeutics
The collaboration will focus on Healis’ clinical program studying the safety and efficacy of CKDB-501A, a BoNT/A neuromodulator, for neuropsychiatry.
First patient in the UK is dosed in the OATD-01 Phase 2 KITE study in pulmonary sarcoidosis
22 mars 2024 04h00 HE
|
Molecure
- OATD-01 is an innovative, first-in-class chitinase inhibitor for the treatment of sarcoidosis among other diseases where chronic inflammation leads to tissue remodeling and fibrosis - In the...
Global Clinical Trial Supplies Market Report 2024-2028 & 2033: New Real-World Evidence Technologies Emerging, Impacting Healthcare Strategy Formulation and Drug Development
20 mars 2024 13h04 HE
|
Research and Markets
Dublin, March 20, 2024 (GLOBE NEWSWIRE) -- The "Clinical Trial Supplies Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The specialized field of clinical...
Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results
13 mars 2024 16h05 HE
|
Quoin Pharmaceuticals, Inc.
Company reported positive initial clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study with positive benefits observed across a number of clinical...